Skip to main content
Premium Trial:

Request an Annual Quote

BGI, University of Edinburgh Ink Genomics Partnership

NEW YORK (GenomeWeb News) – BGI and the University of Edinburgh will partner in an effort aimed at enhancing the university's genomics and bioinformatics activities in biomedical research and livestock studies, BGI said today.

BGI said that under a new memorandum of understanding it will partner with the university through research projects at three Edinburgh facilities: the GenePool Genomics Facility in the School of Biological Sciences, ARK Genomics at the Roslin Institute, and the Genetics Core at the Wellcome Trust Clinical Research Facility and the Institute of Genetics and Molecular Medicine.

"Edinburgh is already a hotbed of expertise in genomics and DNA sequencing, and a partnership with BGI would allow us to expand our work into clinical research and, ultimately, personalized genomics," Mark Blaxter, a University of Edinburgh professor and director of the GenePool Facility, said in a statement.

"This opportunity will keep Edinburgh and Scotland at the very leading edge of all aspects of medical genomics, from rare forms of inherited disease through to major causes of ill health over the life course and in ageing. It will be a crucial bridge between our world leading academic research and the needs of the [National Health Service]," added Professor David Porteus, director of the Genetics Core.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.